---

$17.07

-0.6730 ( -3.79% ) 905.0K

Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2025-05-19	Buy	6000.00	Frohlich Tom